Immunome IMNM
NASDAQ IMNM
$21.34 -0.17 (-0.79%)
As of: Oct 1, 2026 · 9:45 AM EDT

Immunome (IMNM) EBITDA Margin (2023 - 2025)

Updated

Immunome (IMNM) posted EBITDA Margin of -3192.81% for FY2025, up 171.86 percentage points from -3364.67% in FY2024.

Analysis

Immunome (IMNM) EBITDA Margin (2023 - 2025) Analysis & Trends

  • Business Quant data shows IMNM's EBITDA Margin at -3364.67% in FY2024 (-2586.89 pp) and -777.79% in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 35.95%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 49.01%
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 6.02%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 33.11%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 46.01%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -124.26%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 39.10%
10 Immunome 2.44 Bn 410.39 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -1,141.74%
Mar 31, 2025 -1,504.61%
Dec 31, 2024 -3,012.67%
Sep 30, 2024 -1,722.03%
Jun 30, 2024 -1,669.20%
Mar 31, 2024 -12,841.79%
Dec 31, 2023 -2,468.87%
Sep 30, 2023 -126.84%
Jun 30, 2023 -133.05%
Mar 31, 2023 -185.15%
API Access

Immunome EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=IMNM&period=max&api_key=YOUR_API_KEY